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Although PD-1 blockade therapy demonstrates promis-
ing therapeutic effects in a portion of metastatic mela-
noma patients, clinical outcomes remain variable, with
some patients achieving durable responses, others
experiencing early disease worsening followed by later
tumor reduction, while some show no benefit. Thus, it
is critical to identify patients with melanoma who are
most likely to benefit from continued anti-PD-1 therapy,
therefore increasing drug efficacy and decrease toxicity
through a personalized approach to treatment. Since
anti-PD-1 blockade therapy aims to block the interac-
tion of PD-1 and its ligands (i.e. B7-H1/PD-L1), mea-
surement of PD-1 downstream signaling molecule may
enable us to monitor or predict T cell responses to anti-
PD-1 therapy in melanoma patients. In this report, we
established that CD8 T cells expressing high levels of
Bim (a pro-apoptosis molecule) and PD-1 are effector
cells that are responsive to anti-PD-1 therapy. Among
tumor-related CD11a high CD8 T cells in the peripheral
blood of metastatic melanoma patients, Bim expression
was significantly associated with expressions of PD-1
and effector cell markers (T-bet and granzym B). In
human tumor tissues, Bim expression was strongly cor-
related with B7-H1 and PD-1 expression. Genetic
absence of PD-1 prevented Bim up-regulation in tumor-
related CD8 T cells in tumor tissues. B7-H1 fusion pro-
tein or B7-H1-expssred by tumor cells directly induced
Bim protein up-regulation in pre-activated CD8 T cells
via regulation of AKT activation and phosphorylation of
Bim. Bim up-relation was coincident with T cell apopto-
sis induced by B7-H1. In metastatic melanoma patients,
the frequency of Bim+ PD-1+ CD8 T cells significantly
increased in the peripheral blood compared to healthy
donors. Importantly, the baseline frequency of Bim+ per
PD-1+ CD8 T cells in the peripheral blood of melanoma
patients was higher in responders to anti-PD-1 therapy
than in non-responders. After four cycles of anti-PD-1
treatment, the frequency of Bim+ per PD-1+ CD8
T cells dramatically decreased in the peripheral blood of
responders than in non-responders. Our results indicate
that Bim is a downstream signaling molecule of PD-1,
which reflects the degree of PD-1 interaction with its
ligand (B7-H1) in effector CD8 T cells. Measurement of
the frequency of Bim in tumor-related PD-1+ CD8
T cells in the peripheral blood of metastatic melanoma
patients may provide a less invasive method to monitor
or predict responses to anti-PD-1 therapy.
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